Skip to main content
SpringerLink
Log in

Increased survival in melanoma comes at significant cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kandel M, et al. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. European Journal of Cancer 105: 33-40, 29 Oct 2018. Available from: URL: http://dx.doi.org/10.1016/j.ejca.2018.09.026

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Increased survival in melanoma comes at significant cost. PharmacoEcon Outcomes News 816, 18 (2018). https://doi.org/10.1007/s40274-018-5438-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5438-5

Search

Navigation